Higher prevalence of KRAS mutations in colorectal cancer in Saudi Arabia: Propensity for lung metastasis

Publication date: September 2014 Source:Alexandria Journal of Medicine, Volume 50, Issue 3 Author(s): Talha Bader , Abdelsalam Ismail KRAS mutation is widely accepted as a key factor in colorectal tumorigenesis. Although KRAS mutation is widely studied in CRC limited data are available about mutation rates and spectrum in CRC from developing countries like Saudi Arabia where epidemiological features of the disease are different. We studied retrospectively tumor samples of 83 Saudi metastatic CRC patients for KRAS mutations in codon 12 and codon 13, to evaluate the relevance of KRAS mutation positive colorectal cancers with metastatic sites. KRAS mutation was observed in 42.2% (35/83) patients with CRC. The most common mutations were in codon 12 (p.G12D, 46%; 16/35, P <0.0001), codon 12 (pG12V, 31%; 11/35, P <0.0001), and codon 13 (p.G13D, 11%; 4/35, P <0.016). Of these 51% and 23% of the tumors are from the left hemicolon and rectum respectively, 83% were moderately differentiated and 86% were invasive adenocarcinoma. Observed mutations are 74% in patients with advanced stage CRC (P =0.006). Among patients with KRAS mutated CRC (CRC) isolated lung and liver metastases were 32% and 23% whereas in WT KRAS was 3% and 53.1% (P <0.005) respectively. The study revealed 69% and 81% of colorectal patients that responded to treatment with complete response (CR)/partial response (PR)/stable disease (SD) were KRAS mutated and WT KRAS respectively (P =0....
Source: Alexandria Journal of Medicine - Category: Journals (General) Source Type: research